Chiretta — Benefits Deep Dive

Start with the formula problem, because it governs all four pages below. Chiretta (Swertia chirayita — not Andrographis paniculata, the unrelated “green chiretta” sold under an overlapping name) appears in exactly one polyherbal formula that modern medicine has actually put through randomised trials: AYUSH-64, alongside Alstonia scholaris, Caesalpinia crista and Picrorhiza kurroa. That formula has real, modest, meta-analysed human evidence — for COVID-19, a disease with no traditional connection to any of its four ingredients. And when researchers took the formula apart and tested its four components separately in the animal model behind that programme, the antiviral credit went to Alstonia scholaris. Chiretta’s own fraction showed immune modulation without limiting viral load. So the one place a trace of chiretta touched a real modern clinical-trial programme, it was one-quarter of a formula, for a disease it was never traditionally used for, and the best available component-level science says a different plant did the antiviral work.

That is the pattern that repeats across all four claims below: a genuine, often centuries-old tradition; a plausible mechanism; a pharmacology literature that is almost entirely rodent or cell-culture; and, wherever a human signal exists at all, it turns out to belong to a formula, a different species, or a different compound’s generic commercial source — not to Swertia chirayita itself, alone, in a person. Swertia is also an unusually large genus (over 100 species used medicinally across Asia), and its literature shows the ordinary consequence of that: search for chiretta specifically and a large share of what comes back is Swertia mussotii, S. corymbosa, S. kouitchensis, S. punicea or S. longifolia instead. One of the four pages below documents this happening in a single, checkable search.

None of that makes chiretta fraudulent or its tradition worthless — a plant this bitter, used this consistently for two centuries across Ayurveda, Unani and three pharmacopoeias, is not nothing. It means the confident modern claims (“antidiabetic”, “hepatoprotective”, “antimalarial”) sold on the strength of that tradition are carrying far more certainty than the underlying science does, and that the one place real human trial infrastructure touched this plant, the credit for what worked went somewhere else.

Deep-Dive Articles

Back to Table of Contents

Table of Contents

1. Deep-Dive Articles
2. Evidence Ledger
3. A Note on the Genus, Read Before the Rest
4. Key Research: Bitterness and Digestion
5. Key Research: Fever, Malaria and AYUSH-64
6. Key Research: Liver
7. Key Research: Blood Sugar
8. External Resources
9. Connections

Evidence Ledger

Claims ranked by the strength of what actually supports them, not by how confidently they are marketed — and harms and quality problems listed in the same table as benefits, so nothing is hidden below the fold.

Best supported — human, but not an efficacy claim

• A long history of traditional use with no obvious pattern of acute harm at traditional doses. Evidence: two centuries across Ayurveda, Unani and three pharmacopoeias. Verdict: a real, if weak, safety signal — and explicitly not evidence that it works for anything.
• Bitter compounds trigger a measurable cephalic-phase digestive reflex in humans. Evidence: solid, replicated human physiology (TAS2R bitter receptors, salivary and gastric secretory responses). Verdict: established — but this is general bitter-taste physiology, not evidence about this species specifically.

Documented human evidence — for a formula, not the isolated herb

• AYUSH-64 added to standard care modestly shortens COVID-19 symptom duration. Evidence: multiple randomised trials, meta-analysed with GRADE methodology. Verdict: real and human, at the formula level, for an indication with no traditional link to chiretta — and the one study that tested the formula’s four ingredients separately assigned the antiviral activity to a different plant. See the fever and antimalarial page.

Traditional claim, plausible mechanism, no controlled human trial — absent, not negative

• Bitter digestive stimulant, appetite support. Evidence: strong general bitter-receptor mechanism; no chiretta-specific human trial found, and none for true gentian either. Verdict: absent.
• Fever reduction. Evidence: central classical indication; rodent antipyretic screening exists. Verdict: absent in humans; nothing has been tested and failed, but nothing has been tested and passed either.

Laboratory only — rodent or cell-culture, absent in humans

• Antiplasmodial / antimalarial activity. Evidence: extracts and isolated compounds active against Plasmodium in culture and in infected mice. Verdict: absent in humans for the isolated herb; do not substitute for diagnosis and an artemisinin-based combination therapy.
• Hepatoprotective in chemical liver-injury models. Evidence: repeated CCl₄ and paracetamol rodent studies for swertiamarin and amarogentin. Verdict: absent in humans; amarogentin’s species source in these papers is often generic (“Swertia and Gentiana roots”), which weakens even the compound-level attribution to this species.
• Blood-glucose lowering. Evidence: an old (1991–1993) rodent lineage on swerchirin, plus scattered modern work. Verdict: absent in humans; the modern alpha-glucosidase literature searched under chiretta’s own name returns mostly other Swertia species. See the blood-sugar page for the search itself.

Checked and flagged — genus-level quality problems

• “Swertia is a proven antidiabetic genus.” Verdict: overstated. A frequently retrievable Swertia corymbosa antidiabetic paper was retracted by its journal in 2017, and the bulk of alpha-glucosidase-inhibition literature returned by a chiretta-specific search belongs to other species entirely.
• AYUSH-64’s original indication, malaria, resting on solid clinical evidence. Verdict: not supported. The one retrievable primary human record is a two-page 1996 note with no abstract on file; a 2011 review of approved antimalarial phytomedicines lists AYUSH-64 among six, without establishing that it works.

A Note on the Genus, Read Before the Rest

Swertia is a genus of more than 100 species across the Gentianaceae, many of them used medicinally in Chinese, Tibetan and Indian traditional medicine under overlapping common names and overlapping marker compounds — amarogentin, swertiamarin and related xanthones occur across several species, not uniquely in S. chirayita. That matters for a reader trying to check any claim on these four pages directly: a plain-language PubMed search for “chiretta” or even “Swertia chirayita” alongside a mechanism term routinely surfaces work on S. mussotii, S. corymbosa, S. kouitchensis, S. punicea, S. longifolia and others. This page and its four sub-articles label that substitution at every citation where it applies, per this site’s evidence doctrine — rather than once in a preamble that a reader arriving mid-page would never see.

Back to Table of Contents

Key Research: Bitterness and Digestion

1. Chiretta and its bitter taste chemistry — includes the 2025 SAPID taste-deconvolution study of S. chirayita itself.
2. Amarogentin and human bitter taste receptors (TAS2R).
3. Bitter taste receptors and human gastric acid secretion — recent parietal-cell mechanism work.
4. Bitter peptides, gastric digestion and parietal cells.
5. Endocrine taste cells — review — the TAS2R biology behind every bitter-herb claim on this site.
6. McMullen and colleagues, “Bitters: Time for a New Paradigm”, Evidence-Based Complementary and Alternative Medicine, 2015.
7. Bitter tastants and gastric-phase postprandial haemodynamics.
8. Iberogast (STW 5) in functional dyspepsia — 2025 narrative review — a bitter polyherbal with real randomised trials, for comparison.
9. Gentiana lutea (true gentian) — safety and activity in human cell culture — note this is cell culture, not a human trial, even for gentian.
10. Wormwood bitterness and food-cue processing.

Back to Table of Contents

Key Research: Fever, Malaria and AYUSH-64

1. Kumar & Van Staden, review of Swertia chirayita as a traditional medicinal plant, Frontiers in Pharmacology, 2015.
2. Willcox, “Improved traditional phytomedicines in current use for the clinical treatment of malaria”, Planta Medica, 2011 — AYUSH-64 is one of six reviewed.
3. Ali, “Ayush-64 — a new anti-malarial herbal compound”, Indian Journal of Pathology & Microbiology, 1996 — the primary human malaria record; a two-page note with no abstract on file.
4. Swertiamarin and Plasmodium berghei immune modulation in mice, 2022.
5. AYUSH-64 and its four ingredients tested separately in the Syrian hamster COVID-19 model, 2023 — the component-attribution study.
6. AYUSH-64 as adjunct to standard care, randomised multicentric trial, PLoS ONE, 2023.
7. AYUSH therapeutics for COVID-19 — living systematic review and meta-analysis, 2023.
8. AYUSH-64 open-label randomised trial, Chandigarh, 2022.
9. Plant-based add-on drugs for COVID-19 — review of randomised trials, 2023.
10. Malaria rapid diagnostic testing and the cost of delayed treatment.

Back to Table of Contents

Key Research: Liver

1. Swertiamarin and CCl₄-induced hepatotoxicity via the Nrf2/HO-1 pathway, 2017.
2. Amarogentin against CCl₄-induced liver fibrosis in mice, 2017.
3. Serum metabonomics of amarogentin’s hepatoprotective effect, 2018.
4. Swertiamarin and paracetamol (APAP)-induced hepatotoxicity, 2023.
5. Swertiamarin — comprehensive pharmacokinetics and mechanism review, 2025.
6. Amarogentin — pharmacology, patents and toxicity update, 2025.
7. Swertia genus — genetics, chemistry, pharmacology and toxicity, comprehensive review, 2023.
8. Iberogast-associated acute liver injury — case report, 2022 (a different bitter polyherbal product, not chiretta).
9. Silymarin (milk thistle) and liver injury — meta-analysis of randomised trials, 2025.
10. All indexed chiretta hepatoprotective research — run this yourself and check how much is rodent.

Back to Table of Contents

Key Research: Blood Sugar

1. Bajpai and colleagues, hypoglycaemic effect of swerchirin, Planta Medica, 1991 — the origin paper.
2. Saxena and colleagues, mechanism of blood-sugar lowering by a swerchirin-containing fraction, 1993.
3. Saxena and colleagues, comparative study of three hypoglycaemic agents, 1996.
4. Phoboo and colleagues, phenolic-linked rationale for chiretta’s antidiabetic properties, 2013.
5. Chiretta and alpha-glucosidase inhibition — run this yourself; most of the return is other Swertia species.
6. Combined chirata, fenugreek and sesame extract in diabetic rats, 2024 — a three-herb formula, not chiretta alone.
7. Swertia corymbosa antidiabetic paper and its 2017 retraction — a different species, kept here as a genus-wide quality caution.
8. Acarbose versus DPP-4 inhibitors — network meta-analysis — the drug class that already tests chiretta’s most-cited mechanism.
9. Mangiferin and diabetes complications — review — mangiferin is shared with mango leaf, not unique to chiretta.
10. Suryawanshi and colleagues, xanthone and secoiridoid profile of Swertia chirata, 2006.

Back to Table of Contents

External Resources

• PubMed — the index behind every search link on these five pages. Run them yourself; the size of a return is information.
• National Center for Complementary and Integrative Health (NIH).
• LiverTox (NIH) — the reference database for herb- and drug-induced liver injury.
• World Health Organization — Malaria — diagnosis and treatment guidance.
• CITES species checklist — check any plant’s actual trade-protection status yourself.
• PubChem — Amarogentin.

Back to Table of Contents

Connections

• All Herbs
• Chiretta (Main Page) — species identification, the Andrographis mix-up, and the conservation/adulteration problem.
• Chiretta: Bitterness and Digestive Stimulant Action
• Chiretta: Fever and Traditional Antimalarial Use
• Chiretta: Hepatoprotective and Liver Claims
• Chiretta: Blood Sugar and Antidiabetic Claims
• Andrographis — “green chiretta”, the plant chiretta is most often confused with, and the one with actual clinical trials for respiratory infection.
• Milk Thistle — the liver herb with real, if contested, human trial data.
• Berberine — the bitter alkaloid with genuine human glycaemic trials, for contrast with chiretta’s rodent-only blood-sugar story.
• Barberry — another intensely bitter traditional liver-and-digestive herb.
• Fenugreek — the co-ingredient in a chiretta combination study, and a herb with its own real human antidiabetic trial data.
• Neem — the bitter tree that gave chiretta its Sanskrit epithet bhūnimba, “earth neem”.
• Malaria — the disease behind chiretta’s classical fever indication, and why it needs real diagnosis and treatment.
• Liver Disease and Liver Function Tests — how liver injury is actually diagnosed.
• Type 2 Diabetes and Diabetes — the conditions the blood-sugar claim is aimed at.
• Heavy Metals — the contamination risk in wild-collected and imported traditional medicines, relevant to chiretta’s adulteration problem.
• Gastroenterology — digestion, appetite and the conditions bitters are traditionally aimed at.

Back to Table of Contents